NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has given conditional approval for the company's Rosetta Kidney Cancer Test for patient samples originating from New York.

As a result of the conditional approval, the test is now available in all 50 states in the US. However, Rosetta will have to provide any additional information within 60 business days to NYDOH as requested as part of the conditional approval, the Israel-based developer of microRNA-based molecular diagnostics tests said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.